Scisparc Ltd Market Cap ($16.44 Million)
Market Cap & Net Worth: Scisparc Ltd (SPRC)
Scisparc Ltd market cap. Scisparc Ltd (NASDAQ:SPRC) has a market capitalization of $16.44 Million ($16.44 Million) as of October 30, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25624 globally and #5419 in its home market, demonstrating a -46.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scisparc Ltd's stock price $0.71 by its total outstanding shares 23073243 (23.07 Million).
Scisparc Ltd Market Cap History (2021–2026)
Scisparc Ltd market cap history from 2021 to 2026. Data shows change from $3.74 Billion to $16.44 Million (-62.74% CAGR). Check today's stock price for Scisparc Ltd for real-time trading data and today's change.
Index Memberships
Scisparc Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #715 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.00% | #2353 of 3165 |
Weight: Scisparc Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Scisparc Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scisparc Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Scisparc Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
36.66x
Scisparc Ltd's market cap is 36.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $3.74 Billion | $1.07 Million | -$5.80 Million | 3496.17x | N/A |
| 2022 | $453.53 Million | $1.35 Million | -$2.59 Million | 336.69x | N/A |
| 2023 | $112.60 Million | $2.88 Million | -$5.12 Million | 39.11x | N/A |
| 2024 | $8.31 Million | $1.31 Million | -$6.28 Million | 6.36x | N/A |
| 2025 | $31.38 Million | $856.00K | -$12.18 Million | 36.66x | N/A |
Competitor Companies of SPRC by Market Capitalization
Companies near Scisparc Ltd in the global market cap rankings as of October 30, 2026. See net asset quality index of Scisparc Ltd to understand what proportion of total assets are financed by equity.
Key companies related to Scisparc Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Scisparc Ltd (2021–2026)
Market capitalization of Scisparc Ltd from 2021 to today. Between 2021 and today, Scisparc Ltd's market cap moved from $3.74 Billion to $ 16.44 Million, with a yearly change of -62.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $16.44 Million | -47.62% |
| 2025 | $31.38 Million | +277.78% |
| 2024 | $8.31 Million | -92.62% |
| 2023 | $112.60 Million | -75.17% |
| 2022 | $453.53 Million | -87.87% |
| 2021 | $3.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Scisparc Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.44 Million USD |
| MoneyControl | $16.44 Million USD |
| MarketWatch | $16.44 Million USD |
| marketcap.company | $16.44 Million USD |
| Reuters | $16.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more